NBDF/LinkedIn
Jul 28, 2025, 15:18
Investigational Therapies for VWD and Glanzmann Thrombasthenia Unveiled at ISTH 2025: 2 Promising Paths Forward
National Bleeding Disorders Foundation (NBDF) shared a post on LinkedIn:
”Big strides in bleeding disorders care! Hemab Therapeutics shares new data on two potential preventive therapies for Glanzmann thrombasthenia and VWD.”
Read the full update here.
Stay updated on the latest news in hematology with Hemostasis Today.
-
Apr 8, 2026, 18:14Simon Fletcher: See The Unique Challenges PwH Face During Their Gene Therapy Journey
-
Apr 8, 2026, 17:56Hisam Siddiqi: Understanding Bone Marrow Trephine Morphology in MPNs
-
Apr 8, 2026, 17:46Mohamed Reda: Why Some Veins Decide to Take a ‘Detour’?
-
Apr 8, 2026, 17:39Managing Acquired Von Willebrand Syndrome in a Swine Polytrauma Model During ECLS – JTH
-
Apr 8, 2026, 17:04Heghine Khachatryan: Marfan vs LDS – Not All Aortopathies Are the Same
-
Apr 8, 2026, 17:00Frits Rosendaal Receives ISTH Grant Medal for Lifetime Contributions to Thrombosis and Hemostasis Field
-
Apr 8, 2026, 16:25Xiaoying Chen: Teleneurological Ward As A Practical Way to Support High-Quality Stroke Care Beyond Major Centres
-
Apr 8, 2026, 16:24Ney Carter Borges: Endocrine Drivers of Resistant Hypertension – Insights from the MOMENTUM Trial at ACC 26
-
Apr 8, 2026, 16:21Jonathan Gelber: Exploring Papaya Extract as an Option to Elevate Platelet Numbers Before PRP